MEDIF - MediPharm Labs Corp. (MEDIF) Q4 2023 Earnings Call Transcript
2024-03-27 15:20:26 ET
MediPharm Labs Corp. (MEDIF)
Q4 2023 Earnings Conference Call
March 27, 2024 08:30 ET
Company Participants
David Pidduck - Chief Executive Officer
Keith Strachan - President
Greg Hunter - Chief Financial Officer
Conference Call Participants
Aaron Grey - Alliance Global Partners
Scott Fortune - ROTH MKM
Presentation
Operator
Ladies and gentlemen, thank you for standing by and welcome to the MediPharm Labs 2023 Fourth Quarter and Full Year Financial Results Conference Call. Please be advised that today's conference call is being recorded.
Before we begin, please note that remarks today may contain forward-looking information and forward-looking statements within the meaning of applicable security laws. This includes, without limitation, statements about MediPharm Labs and its current and future plans, expectations, intentions, financial results, levels of activity, performance, goals or achievements and other future events, trends, profitability, business growth or development. Forward-looking statements are made as of the date hereof based on information currently available to management of MediPharm and on estimates and assumptions made based on factors that MediPharm believes are appropriate and reasonable in the circumstances. However, there can be no assurance that such estimates and assumptions will prove to be correct. Many factors could cause actual results to differ materially from those expressed or implied by forward-looking statements. Additional information is contained in MediPharm Labs' filings with the Canadian and provincial security regulators which are available on SEDAR at sedar.com.
The company's remarks may also contain references to certain non-IFRS financial measures, including EBITDA, adjusted EBITDA, growth, gross profit and adjusted gross profit. These measures do not have any standardized meanings according to the International Financial Reporting Standards or IFRS and therefore, may not be comparable to similar measures presented by other companies. MediPharm believes that nonprofit IFRS measures reference provided information useful to shareholders and investors in understanding our performance and may assist in the evaluation of the combined company's business relative to that of its peers. For more information, please see the section titled Reconciliation of non-IFRS measures, the most recent MD&A of MediPharm which is available on SEDAR.
I will now pass the call over to David Pidduck, Chief Executive Officer of MediPharm. Please go ahead, sir.
David Pidduck
Thank you, operator and good morning, everyone. We appreciate you joining us for MediPharm Labs Q4 and 2023 Year-end Conference Call. Joining me on the call today are Keith Strachan, MediPharm's President; and Greg Hunter, the company's Chief Financial Officer. I will address some of our highlights for the year and then hand the call over to Keith and Greg to provide more insights on the quarterly results and full year results....
MediPharm Labs Corp. (MEDIF) Q4 2023 Earnings Call Transcript